Treatment predictors of a sustained virologic response in hepatitis B and C
Open Access
- 1 October 2008
- journal article
- review article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 49 (4), 634-651
- https://doi.org/10.1016/j.jhep.2008.07.013
Abstract
Treatment predictors are important tools for the management of therapy in patients with chronic hepatitis B and C virus (HBV, HCV) infection. In chronic hepatitis B, several pretreatment parameters have been identified for prediction of virologic response to interferon alfa-based antiviral therapies or treatment with polymerase inhibitors. In interferon alfa and pegylated interferon alfa-treated patients, low baseline HBV DNA concentrations, HBV genotype A (B), and high baseline ALT levels are significantly associated with treatment response. In patients treated with nucleos(t)ide analogues, low baseline HBV DNA but not viral genotype is positively associated with virologic response. During treatment the best predictor of response is HBV DNA kinetics. Early viral suppression is associated with favourable virologic response and reduced risk for subsequent resistance mutations. For the current standard treatment with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C, infection with HCV genotypes 2 and 3, baseline viral load below 400,000-800,000 IU/ml, Asian and Caucasian ethnicity, younger age, low GGT levels, absence of advanced fibrosis/cirrhosis, and absence of steatosis in the liver have been identified as independent pretreatment predictors of a sustained virologic response. After initiation of treatment, initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR) is the best predictor of sustained virologic response independent of HCV genotype.Keywords
This publication has 195 references indexed in Scilit:
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology, 2007
- Impact of steatosis on progression of fibrosis in patients with mild hepatitis CHepatology, 2004
- The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis BThe Esophagus, 2004
- Baseline ALT level does not predict viral load reduction in response to Entecavir therapyJournal of Hepatology, 2003
- Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?Journal of Hepatology, 2002
- Hepatic iron contents and response to interferon-α in patients with chronic hepatitis CDigestive Diseases and Sciences, 1996
- Response to interferon α therapy is influenced by the iron content of the liverJournal of Hepatology, 1994
- Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infectionJournal of Hepatology, 1992
- Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type BJournal of Hepatology, 1990
- Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre studyJournal of Hepatology, 1990